# Sepsis (severe sepsis or septic shock) treatment with corticosteroids

A living systematic review

Short url: http://openmetaanalysis.github.io/sepsis-steroids

**Clinical summary:** This meta-analysis suggests that low dose corticosteroids in patients with septic shock who are hypotensive despite pressors *is* effective at reducing mortality (relative risk 0.91; 95% CI 0.84 to 0.99). The most effective therapy appears to be hydrocortisone for 200 mg per day for seven days. 

While the previous Cochrane Collaboration (citation below) found significant benefit among all patients with septic shock, the Cochrane used Mantel-Haenszel fixed estimator. This method may be too optimistic because the heterogenteity as measured by I<sup>2</sup> was '[moderate](http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm)' at 57%. In this setting the Knapp-Hartung estimator may be better (PMID: [24727843](https://pubmed.gov/24727843)).

Exploration of heterogeneity of results is limited by inconsistent reporting of co-treatments such as volumes of fluids and duration of pressors prior to receiving steroids. It is not clear that patients in recent trials received 30 ml/kg fluids prior to receiving pressors and steroids. 

Among the four largest trials, CORTICUS was the only one without a trend towards reduction in mortality. Of the four trials, CORTICUS continued steroids for 11 days while the other three stopped at 7 days.

The benefit among vasopressor-dependent patients does not depend on their adrenal status or co-administration of fludrocortisone (see [additional forest plots](files/forest-plots))

Two dose finding studies, that were excluded (links are below) due to not having a control group, suggest 100 mg per day of hydrcortisone may be more effective and need further examination.

Meta-regression dooes not find modulators (year of publication, study size, event rate in the control groups) on the effect of the intervention.
* [Reconciliation of conclusions with prior meta-analyses](files/reconciliation-tables/Reconciliation%20of%20conclusions.pdf)
* [Keep current with this topic](files/searching/Keep-up.md)

Acknowledgement: we acknowledge the essential work by the authors of the prior systematic review(s) listed below.

**Methods overview:** This repository is an [openMetaAnalysis](https://openmetaanalysis.github.io/) that combines methods of scoping, rapid, and living systematic reviews.  This analysis updates one or more previously published review(s).(1) A comparison of studies include in this review compared to prior reviews are in the table, [reconciliation of trials included with prior meta-analyses](files/reconciliation-tables/Reconciliation%20of%20studies.pdf). Newer studies included are listed in the references below. Rationale for newer trials excluded may be listed at the end of the references. 
* [Methods](http://openmetaanalysis.github.io/methods.html) for openMetaAnalysis
* [Evidence search](files/searching/evidence-search.md) for this review

**Results:** Details of the studies included are in the:
* [Reconciliation of trials included with prior meta-analyses/](files/reconciliation-tables/Reconciliation%20of%20studies.pdf) (under construction)
* [Description of studies (PICO table)](files/study-details/table-pico.pdf) (under construction)
* [Risk of bias assessment](files/study-details/table-bias.pdf) (under construction)
* [Forest plots](files//forest-plots) ([source data](files/data))
* [Meta-regressions](files//metaregression) ([source data](files/data))
* [Reconciliation of conclusions with prior meta-analyses](files/reconciliation-tables/Reconciliation%20of%20conclusions.pdf)

The forest plot for the primary outcomes are below. Additional [forest plots](files/forest-plots) of secondary analyses may be available. 

![Principle results for benefit](files/forest-plots/Outcome-Primary.png "Principle results for benefit]")

The meta-regression for the primary outcomes are below. Additional [meta-regressions](files/metaregression) of secondary analyses may be available. 

![Principle results for benefit](files/metaregression/Outcome-Primary.png "Principle results for benefit]")

References:
----------------------------------
### Systematic review(s)
#### Most recent review(s) at time of last revision of this repository
1. Gibbison B, López-López JA, Higgins JP, Miller T, Angelini GD, Lightman SL, Annane D. Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care. 2017 Mar 28;21(1):78. doi: [10.1186/s13054-017-1659-4](http://dx.doi.org/10.1186/s13054-017-1659-4). PMID: [28351429](http://pubmed.gov/28351429); PMCID: [PMC5371269](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371269/)
2. Volbeda M, Wetterslev J, Gluud C, Zijlstra JG, van der Horst IC, Keus F. Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015 Jul;41(7):1220-34. doi: [10.1007/s00134-015-3899-6](http://dx.doi.org/10.1007/s00134-015-3899-6). PMID: [26100123](http://pubmed.gov/26100123); PMCID: [PMC4483251](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483251/)
3. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015 Dec 3;(12):CD002243. doi: [10.1002/14651858.CD002243.pub3](http://dx.doi.org/10.1002/14651858.CD002243.pub3). PMID: [26633262](http://pubmed.gov/26633262)

### Randomized controlled trials that are more recent
1. Lv QQ, Gu XH, Chen QH, Yu JQ, Zheng RQ. Early initiation of low-dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial. Am J Emerg Med. 2017 Jun 5. pii: S0735-6757(17)30444-8. doi: 10.1016/j.ajem.2017.06.004. PMID: [28615145](http://pubmed.gov/28615145)
2. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E; CRICS-TRIGGERSEP Network. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018 Mar
1;378(9):809-818. doi: 10.1056/NEJMoa1705716. PMID: [29490185](http://pubmed.gov/29490185)
3. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, Joyce C, Li Q, McArthur C, Perner A, Rhodes A, Thompson K, Webb S, Myburgh J; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018 Mar 1;378(9):797-808. doi: 10.1056/NEJMoa1705835. Epub 2018 Jan 19. PMID: [29347874](http://pubmed.gov/29347874)
4. Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, et al; SepNet–Critical Care Trials Group.. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. JAMA. 2016 Nov 1;316(17):1775-1785. doi: [10.1001/jama.2016.14799](http://dx.doi.org/10.1001/jama.2016.14799). PMID: [27695824](http://pubmed.gov/27695824).

#### New study(s) undergoing review
1. Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, Meduri GU. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016 Oct 15;20(1):329. PMID: [27741949](http://pubmed.gov/27741949); PMCID: [PMC5065699](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27741949/)
2. Mirea L, Ungureanu R, Pavelescu D, Grintescu I, Dumitrache C, Grintescu I, et al. Continuous administration of corticosteroids in septic shock can reduce risk of hypernatremia. Critical Care. 2014 Mar 17;18(1):P239.  https://doi.org/10.1186/cc13429
3. Mirea L, Ungureanu R, Pavelescu D, Grintescu I, Dumitrache C, Mirea D, et al. Impact of corticosteroid administration in septic shock on glycemic variability. Critical Care. 2014 Mar 17;18(1):P445. https://doi.org/10.1186/cc13635


#### New study(s) *excluded* 
1. Ngaosuwan K, Ounchokdee K, Chalermchai T. Clinical Outcomes of Minimized Hydrocortisone Dosage of 100 mg/day on Lower Occurrence of Hyperglycemia in Septic Shock Patients. Shock. 2017 Nov 15. doi: [10.1097/SHK.0000000000001061](http://dx.doi.org/10.1097/SHK.0000000000001061). PMID: [29176402](http://pubmed.gov/29176402). *Compared hydrocortisone 200 mg/day vs 100 mg/day*
2. Hyvernat H, Barel R, Gentilhomme A, Césari-Giordani JF, Freche A, Kaidomar M,  Goubaux B, Pradier C, Dellamonica J, Bernardin G. Effects of Increasing Hydrocortisone to 300 mg Per Day in the Treatment of Septic Shock: a Pilot Study. Shock. 2016 Nov;46(5):498-505. PMID: [27405061](http://pubmed.gov/27405061) *Compared hydrocortisone 300 mg/day vs 200 mg/day*
3. Huh JW, Choi HS, Lim CM, Koh Y, Oh YM, Shim TS, Lee SD, Kim WS, Kim DS, Hong SB. Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3days with 7days. Respirology. 2011 Oct;16(7):1088-95. doi:[ 10.1111/j.1440-1843.2011.02018.x](http://dx.doi.org/ 10.1111/j.1440-1843.2011.02018.x). PMID: [21726354](http://pubmed.gov/21726354) *Compared hydrocortisone 100 mg/day for 3 days versus 7 days*
4. Chen Z, Yang C, He H, He Z. The impacts of low-dose corticosteroids infusion given in different manners on refractory septic shock patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Jun;27(6):443-7. doi: [10.3760/cma.j.issn.2095-4352.2015.06.006](http://dx.doi.org/10.3760/cma.j.issn.2095-4352.2015.06.006). Chinese. PMID: [26049181](http://pubmed.gov/26049181). *Compared modes of steroid therapies*


-------------------------------
[Cite and use this content](https://github.com/openMetaAnalysis/openMetaAnalysis.github.io/blob/master/reusing.MD)  - [License](files/LICENSE.md) - [Edit this page](../../edit/master/README.md) - [History](../../commits/master/README.md)  - 
[Issues and comments](../../issues?q=is%3Aboth+is%3Aissue)

